Introduction
Paraganglia are groups of chromaffin cells of neural crest origin (neuroendocrine) distributed all over the body. They sense fluctuations in blood pH and oxygen ten-
Material and Methods
A 47-year-old previously healthy male presented with a painless right inferior, right orbital, non-pulsatile mass causing mild exophthalmos and diplopia. Visual acuity and ocular movements were preserved. The rest of the physical examination was unremarkable. No relevant previous medical or family history was noted. On imaging, the lesion was described as an enhancing mass inferior to the right globe, abutting the right orbital canal, measuring 13 × 13 mm and causing mild upward globe displacement ( fig. 1 a) .
A biopsy was performed with clinical notes indicating a profusely vascular tumour. Macroscopically, the lesion was composed of multiple fragments of haemorrhagic fleshy tumour. The histopathology analysis revealed nests of polygonal cells, both chromogranin and synaptophysin positive ( fig 1 d, e) , with S100-positive sustentacular cells ( fig. 1 f) , amongst a delicate vascular stroma. Zellballen were highlighted with reticulin stain. The tumour nuclei were oval, hyperchromatic and showed focal nuclear pleomorphism ( fig. 1 b, c) 38 formed included cytokeratin A1/A3, CK7, CD10, Melan A, SMA and CD34; all of them were negative. Double staining with SDHB stain (red) and CD31 (brown) showed granular cytoplasmic staining in tumour cells with a positive internal control in endothelial cells, a pattern of staining consistent with a positive result ( fig. 1 g) . In consequence, SDH gene mutational analysis was not recommended in this case (SDH-negative staining, which is an indicator of complex II disruption caused by SDHx mutations).
Discussion
Paragangliomas are rarely seen in the head and neck region (less than 3%), and very rarely, this tumour may be seen within the orbit, with fewer than 40 cases reported in the literature [1, 5] . Paragangliomas show a definite familial incidence, with up to 35% of these tumours being hereditary [4] .
This tumour usually follows a benign clinical course (90%). It is slow growing and may remain stable for years [5, 6] . There is an overall incidence of malignant transformation of about 10%, with no reliable histological criteria that predict malignancy. The only reliable criterion for malignancy is metastasis [5, 7, 8] . However, recent publications have suggested that a lack of SDHB staining in paraganglioma cells is a marker of adverse outcome in both sporadic and familial PCC/PGL [9] . The possibility of metastatic paraganglioma was contemplated in view that the lesion was not arising from the ciliary ganglion or ciliary nerve sustentacular tissue.
Molecular and genetic studies have identified germline mutations of six genes that contribute to the development of PCC/PGL in patients: RET ('rearranged during transfection' proto-oncogene, predisposing to multiple endocrine neoplasia), VHL (predisposing to von Hippel-Lindau syndrome), NF1 (associated with neurofibromatosis type 1) and SDH [10] . SDH subunit mutations (SDHB, SDHC and SDHD) predispose to PCC/ PGL syndromes that otherwise may be regarded as sporadic in nature, because many of the patients do not display the expected clinical association with multifocal disease, young age and/or positive family history [4, 10, 11] .
SDH is an enzyme complex that catalyzes the oxidation of succinate to fumarate in the citric acid cycle and participates in the electron transport chain. SDH is located in the mitochondrial inner membrane and consists of four nuclear-encoded subunits: the flavoprotein SDHA, the iron-sulfur protein SDHB and the integral membrane proteins SDHC and SDHD [4, 11] . Burnichon et al. [11] supported previous findings of the high frequency of SDH mutations in head and neck paragangliomas, as well as a higher frequency of abdominal and pelvic disease and overall malignancy in SDH mutations. In PCC/PGL, the absence of SDH staining by immunohistochemistry is an indicator of complex II disruption caused by SDHB, SDHC or SDHD mutations [4] and has been reported as a marker to predict malignancy [9] . Mutations in the tumour suppressor gene SDH family, referred to collectively as SDHx, occur in patients with the PCC/PGL syndromes.
Following SDHB immunohistochemical evaluation, SDHx gene mutational analysis is performed on the tumours with negative SDHB immunohistochemistry [9] . Our case showed granular cytoplasmic staining in tumour cells with a positive internal control in endothelial cells with SDHB immunohistochemistry stain, a pattern of staining consistent with a positive result, hence not requiring genetic analysis. Systemic imaging including CT of the abdomen and chest X-ray showed no evidence of an extraorbital mass or renal/adrenal mass, eliminating the orbit as a possible secondary site.
Conclusion
In summary, a paraganglioma is of rare occurrence in the orbit and should alert clinicians for further investigation in search for a possible primary site outside the orbit. SDHB immunohistochemical staining can triage patients for genetic testing for paragangliomas, given its well-known familial predisposition in up to 35% of cases as well as its description as a marker to predict malignancy.
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